The patient-derived cancer stem cells abundantly expressed CD133 and SOX2, which are related to recurrence [48]; importantly, these molecules were effectively inhibited by (Z)-BP during cancer cell proliferation, implying that high concentrations of (Z)-BP could increase the distance of drug penetration into residual tumors or other brain areas, compared with GW [29], thereby controlling disease recurrence (Figure 4). The gene discussed is SOX2; the disease is cancer.